e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response
ABL1 fusion gene in chronic myeloid leukemia (CML). The current goal with tyrosine kinase inhibitors (TKI) is to achieve sustained deep molecular response (DMR) in order to discontinue TKI treatment and remain in the so-called treatment-free remission (TFR) phase, but biological factors associated with these goals are not well established. This study aimed to determine the effect of transcript type on TFR in patients receiving frontline treatment with imatinib (IM) or second-generation TKI (2G-TKI). Patients treated at least 119 months with IM presented less post-discontinuation relapse than those that discontinued IM before 119 months (p = 0.005). In addition, cases with the e14a2 transcript type treated at least 119 months with IM presented a better TFR (p = 0.024). On the other hand, the type of transcript did not affect the cytogenetic or molecular response in 2G-TKI treated patients; however, the use of 2G-TKI may be associated with higher and earlier DMR in patients with the e14a2 transcript.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 13(2024), 3 vom: 29. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Marcé, Sílvia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BCR::ABL1 transcript type |
|---|
| Anmerkungen: |
Date Revised 12.02.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcm13030779 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368269655 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368269655 | ||
| 003 | DE-627 | ||
| 005 | 20240212232136.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240210s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm13030779 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1289.xml |
| 035 | |a (DE-627)NLM368269655 | ||
| 035 | |a (NLM)38337473 | ||
| 035 | |a (PII)779 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Marcé, Sílvia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a e13a2 and e14a2 are the most frequent transcript types of the BCR::ABL1 fusion gene in chronic myeloid leukemia (CML). The current goal with tyrosine kinase inhibitors (TKI) is to achieve sustained deep molecular response (DMR) in order to discontinue TKI treatment and remain in the so-called treatment-free remission (TFR) phase, but biological factors associated with these goals are not well established. This study aimed to determine the effect of transcript type on TFR in patients receiving frontline treatment with imatinib (IM) or second-generation TKI (2G-TKI). Patients treated at least 119 months with IM presented less post-discontinuation relapse than those that discontinued IM before 119 months (p = 0.005). In addition, cases with the e14a2 transcript type treated at least 119 months with IM presented a better TFR (p = 0.024). On the other hand, the type of transcript did not affect the cytogenetic or molecular response in 2G-TKI treated patients; however, the use of 2G-TKI may be associated with higher and earlier DMR in patients with the e14a2 transcript | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BCR::ABL1 transcript type | |
| 650 | 4 | |a chronic myeloid leukemia | |
| 650 | 4 | |a discontinuation | |
| 650 | 4 | |a treatment free remission | |
| 650 | 4 | |a tyrosine kinase inhibitors | |
| 700 | 1 | |a Méndez, Aleix |e verfasserin |4 aut | |
| 700 | 1 | |a Xicoy, Blanca |e verfasserin |4 aut | |
| 700 | 1 | |a Estrada, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Cabezón, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Sturla, Antonella Luciana |e verfasserin |4 aut | |
| 700 | 1 | |a García, Miriam Ratia |e verfasserin |4 aut | |
| 700 | 1 | |a Angona, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Amat, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Escribano Serrat, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Scalzulli, Emilia |e verfasserin |4 aut | |
| 700 | 1 | |a Morgades, Mireia |e verfasserin |4 aut | |
| 700 | 1 | |a Senín, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Boluda, Juan Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrer-Marín, Francisca |e verfasserin |4 aut | |
| 700 | 1 | |a Anguita, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Cortés, Montserrat |e verfasserin |4 aut | |
| 700 | 1 | |a Plensa, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Breccia, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a García-Gutierrez, Valentín |e verfasserin |4 aut | |
| 700 | 1 | |a Zamora, Lurdes |e verfasserin |4 aut | |
| 700 | 0 | |a Grupo Español de Leucemia Mieloide Crónica (GELMC) |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 13(2024), 3 vom: 29. Jan. |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g number:3 |g day:29 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm13030779 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |e 3 |b 29 |c 01 | ||